Clinical Determinants of Longitudinal Disability in LGI-1-IgG Autoimmune Encephalitis
Open Access
- 1 January 2024
- journal article
- research article
- Published by Wolters Kluwer Health in Neurology Neuroimmunology & Neuroinflammation
- Vol. 11 (1)
Abstract
Background and Objectives Longitudinal outcome studies in leucine-rich glioma inactivated-1 (LGI-1) immunoglobulin G (IgG) autoimmune encephalitis (AE) are needed to inform clinical management and prognostication. This study aims to evaluate longitudinal predictors of disability and disease severity in LGI-1-IgG AE. Methods This retrospective observational study of patients with LGI-1-IgG AE was conducted between 2013-2022. Disability and disease severity were defined by scores on the modified Rankin Scale (mRS) and the clinical assessment scale in AE (CASE), respectively. Demographic variables, clinical/paraclinical data, brain MRI, and Montreal Cognitive Assessment (MOCA) scores were examined as predictors of mRS and CASE scores in logistic and linear regression models, respectively. Results Thirty patients (60% male, median age = 68.5; interquartile range (IQR) = 63.0–75.0) were included, with a median follow-up time of 19.1 months (IQR = 5.3–47.1) The majority developed seizures (29, [97%]) and/or cognitive impairment (30, [100%]) and received acute (27, [90%]) and maintenance (23 [77%]) immunotherapy. The median initial MOCA was 23/30 (IQR = 21.0–25.0). Baseline mRS (median = 2.0, IQR = 2.0–3.0) and CASE (mean = 4.3, SD = 3.7) correlated with one another (r = 0.58, p < 0.001) and with initial MOCA score (mRS r = –0.60, p = 0.012; CASE r = –0.56, p = 0.021) After 12 months from symptom onset, mRS (OR = 0.88, [95% CI = 0.82–0.94], p < 0.001) and CASE (β = −0.03, [SE = 0.01], p < 0.001) improved significantly. Lower initial MOCA score (OR = 0.68, 95% CI = 0.47–0.98, p = 0.041) and temporal lobe(s) T2 hyperintensity (OR = 16.50, 95% CI = 2.29–119.16, p = 0.006) were associated with higher mRS longitudinally. At last follow-up, most patients had persistent memory dysfunction (25, [83%]) while few had ongoing seizure activity (3, [10%]). Discussion Overall, there was a high degree of correlation between mRS and CASE scores in patients with LGI-1-IgG AE, with both scores improving significantly after 12 months. Memory dysfunction and psychiatric disturbance were the most prevalent longitudinal symptoms. Cognitive impairment and temporal lobe T2 hyperintensity at baseline were both associated with greater disability at long-term follow-up, underscoring these as important determinants of disability outcomes in LGI-1-IgG AE.Keywords
This publication has 19 references indexed in Scilit:
- Anti-LGI1 encephalitisNeurology, 2016
- Anti-LGI1–associated cognitive impairmentNeurology, 2016
- A clinical approach to diagnosis of autoimmune encephalitisThe Lancet Neurology, 2016
- Faciobrachial dystonic seizures: the influence of immunotherapy on seizure control and prevention of cognitive impairment in a broadening phenotypeBrain, 2013
- Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan’s syndrome and acquired neuromyotoniaBrain, 2010
- The Patient Health Questionnaire Somatic, Anxiety, and Depressive Symptom Scales: a systematic reviewGeneral Hospital Psychiatry, 2010
- Optimizing Cutoff Scores for the Barthel Index and the Modified Rankin Scale for Defining Outcome in Acute Stroke TrialsStroke, 2005
- The Montreal Cognitive Assessment, MoCA: A Brief Screening Tool For Mild Cognitive ImpairmentJournal of the American Geriatrics Society, 2005
- Potassium channel antibody‐associated encephalopathy: a potentially immunotherapy‐responsive form of limbic encephalitisBrain, 2004
- Interobserver agreement for the assessment of handicap in stroke patients.Stroke, 1988